BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Alkermes plc 

852 Winter Street

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-609-6000 Fax: n/a


About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermes' website at

Key Executives
Richard F. Pops
Chairman and Chief Executive Officer

Shane Cooke

Kathryn L. Biberstein
Senior Vice President, General Counsel and Secretary, and Chief Compliance Officer

Mark Stejbach
Senior Vice President, Chief Commercial Officer

Georgianna Harris
Vice President, Regulatory Affairs

Madeline D. Coffin
Vice President, Human Resources

Elliot W. Ehrich, M.D.
Senior Vice President, Research and Development, and Chief Medical Officer

James M. Frates
Senior Vice President, Chief Financial Officer

Blair C. Jackson
Vice President, Business Development

Michael J. Landine
Senior Vice President, Corporate Development

Rebecca J. Peterson
Senior Vice President, Corporate Communications

Gordon G. Pugh
Senior Vice President, Chief Operating Officer and Chief Risk Officer

Peter Norman
Vice President, Government Affairs and Policy

Srdjan Stankovic
Senior Vice President, Clinical Development and Medical Affairs


Alkermes Corporate Headquarters
Connaught House
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000

Waltham, Massachusetts
852 Winter Street
Waltham, MA 02451
+1 781 609 6000

Athlone, Ireland
Monksland, Athlone
Co Westmeath, Ireland
+353 90 649 5000

Gainesville, Georgia
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100

Wilmington, Ohio
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642

 Key Statistics

Ownership: Public

Web Site: Alkermes
Employees: 1,200
Symbol: ALKS

Drug Delivery

 Company News
Alkermes (ALKS) To Present Clinical Data On ALKS 8700 At Annual Meeting Of The Consortium Of Multiple Sclerosis Centers 5/29/2015 11:49:04 AM
Alkermes (ALKS) To Present Clinical Data On ALKS 8700 At Annual Meeting Of The Consortium Of Multiple Sclerosis Centers 5/29/2015 9:24:49 AM
Alkermes (ALKS)’ Corporate Presentation To Be Webcast At The Jefferies and Co. 2015 Global Healthcare Conference 5/27/2015 10:56:07 AM
Alkermes (ALKS)’ Corporate Presentation To Be Webcast At The UBS Global Healthcare Conference 5/12/2015 11:13:03 AM
Alkermes (ALKS) Reports First Quarter 2015 Financial Results 4/30/2015 12:36:03 PM
Alkermes (ALKS) To Host Conference Call To Discuss First Quarter 2015 Financial Results 4/23/2015 8:20:19 PM
Alkermes (ALKS) To Present Preclinical Data On Novel Selective Effector Cell Activator (SECA) Immuno-Oncology Candidate At Upcoming American Association for Cancer Research Annual Meeting 4/13/2015 8:27:48 AM
Recro Pharma (REPH) Completes Acquisition Of IV/IM Meloxicam And CGMP Manufacturing Facility And Business Unit From Alkermes (ALKS) 4/13/2015 7:54:51 AM
Alkermes (ALKS) Announces Positive Topline Results From Complete Six-Month Phase 2 Clinical Trial Of ALKS 3831 In Schizophrenia 4/6/2015 7:54:50 AM
Alkermes (ALKS) To Present Data On Aripiprazole Lauroxil And ALKS 3831 At 15th International Congress On Schizophrenia Research 3/23/2015 9:37:21 AM